medigraphic.com
ISSN 1561-2988 (Impreso)

2014, Número 4

<< Anterior Siguiente >>

Rev Cubana Farm 2014; 48 (4)


Efectos del bloqueo del sistema EGF/EGFR sobre la cicatrización de las heridas en pacientes oncológicos

Casacó PÁR, Fernández LA

Idioma: Español
Referencias bibliográficas: 62
Paginas: 684-700
Archivo PDF: 207.96 Kb.


RESUMEN

La administración de drogas que bloquean el sistema del factor de crecimiento epidérmico y su receptor ha demostrado efectos beneficiosos en pacientes con tumores sólidos de origen epitelial. Cada día resulta más frecuente el uso de múltiples modalidades terapéuticas para combatir estos tumores, las cuales incluyen la asociación de agentes blanco y cirugía. Los agentes que actúan sobre dicho sistema pudieran causar trastornos de la cicatrización al bloquear vías del sistema que también intervienen en la cicatrización de las heridas. El objetivo de este artículo es revisar y comentar acerca del conocimiento de la relación entre el uso de las drogas anti-EGF/EGFR y los trastornos en la cicatrización de las heridas. La búsqueda bibliográfica se realizó en PubMed y Google (solo en español e inglés) y se tuvo en cuenta cualquier publicación encontrada hasta enero del 2014. Se incluyeron los anticuerpos monoclonales cetuximab, panitumumab y nimotuzumab; las pequeñas moléculas erlotinib y gefitinib y las vacunas terapéuticas contra el cáncer CIMAvax EGF y HER-1. Se hace especial énfasis en los biofarmacéuticos nimotuzumab, CIMAvax EGF y HER-1; producidos en el Centro de Inmunología Molecular, La Habana, Cuba, debido a su amplio uso en Cuba y otros países de América Latina. No se encontraron evidencias de relación entre el uso de estos productos y la aparición de trastornos en la cicatrización de las heridas. Dado que los tratamientos anti-EGF/EGFR también inhiben la proliferación celular que induce el drenaje de las heridas y la migración celular inducida por las radiaciones, se sugiere que el tratamiento anti-EGF/EGFR no debe suspenderse, ni antes ni después de la cirugía y sus posibles efectos deben ser vigilados. Obviamente, se necesitan ulteriores investigaciones por parte de los farmacólogos no clínicos y clínicos, oncólogos clínicos y cirujanos oncológicos para entender mejor los procesos fisiopatológicos de cicatrización en los cánceres de origen epitelial.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hompes D, Ruers T. Review: Incidence and clinical significance of Bevacizumabrelated non-surgical and surgical serious adverse events in metastatic colorectal cancer. Eur J Surg Oncol. 2011;37:737-46.

  2. Casacó A, Fuentes D, Ledón N, Fernandez A, Crombet T. Anti-epidermal growth factor/epidermal growth factor receptor therapeutic anti-cancer drugs and the wound healing process. J Cancer Science and Therapy. 2012;4(10):324-9.

  3. Kaftan H, Reuther L, Miehe B, Hosemann W, Herzog M. Delay of tympanic membrane wound healing in rats with topical application of a tyrosine kinase inhibitor. Wound Rep Reg. 2008;16:364-9.

  4. Lee SM, Buchler T, Joseph T, Lai C. Bilateral eardrum perforation after long-term treatment with erlotinib. J Clin Oncol. 2008;26:2582-9.

  5. Márquez EB, De Ortueta D, Royo SB, Martínez-Carpio PA. Epidermal growth factor receptor in corneal damage: update and new insights from recent reports. Cutan Ocul Toxicol. 2011;30:7-14.

  6. Martin P. Wound healing-aiming for perfect skin regeneration. Science. 1997;276:75-81.

  7. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453:314-21.

  8. Müller AK, Meyer M, Werner S. The roles of receptor tyrosine kinases and their ligands in the wound repair process. Semin Cell Dev Biol. 2012;23(9):963-70.

  9. Werner S, Grose R. Regulation of Wound Healing by Growth Factors and Cytokines. Physiol Rev. 2003;83:835-70.

  10. Clark RAF. Wound repair. Overview and general considerations. In: Clark RAF, editor. The Molecular and Cellular Biology of Wound Repair. 2nd ed. New York: Plenum; 1996. p. 3-50.

  11. Mackool RJ, Gittes GK, Longaker MT. Scarless healing. The fetal wound. Clin Plast Surg. 1998;25:357-65.

  12. Martin P. Wound healing-aiming for perfect skin regeneration. Science. 1997;276:75-81.

  13. Repertinger SK, Campagnaro E, Fuhrman J, El-Abaseri T, Yuspa SH, Hansen LA. EGFR enhances early healing after cutaneous incisional wounding. J Invest Dermatol. 2004;123:982-9.

  14. Strachan L, Murison JG, Prestidge RL, Sleeman MA, Watson JD, Kumble KD. Cloning and biological activity of epigen, a novel member of the epidermal growth factor superfamily. J Biol Chem. 2001;276:18265-71.

  15. Fuentes D, Chacón L, Casacó A, Ledón N, Fernández N, Iglesias A, et al. Effects of an epidermal growth factor receptor-based cancer vaccine in the wound healing and inflammation processes in murine experimental models. Int Wound J. 2012 Sep 4. doi: 10.1111/j.1742-481X.2012.01074.x.

  16. Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest. 1984;74:647-51.

  17. Perez R, Pascual M, Macias A, Lage A. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat. 1984;4:189-93.

  18. Gullick WJ, Marsden JJ, Whittle N, Ward B, Bobrow L, Waterfield MD. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res. 1986;46:285-92.

  19. Lockhart C, Berlin JD. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol. 2005;32:52-60.

  20. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 1993;11:1873-8.

  21. Tan X, Egami H, Ishikawa S, Nakagawa M, Ishiko T, Kamohara H, et al. Relationship between activation of epidermal growth factor receptor and cell dissociation in pancreatic cancer. Int J Oncol. 2004;25:1303-9.

  22. Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee WK, Matsutani M. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol 2004;21:53-6.

  23. Carroll RS, Black PM, Zhang J, Kirsch M, Percec I, Lau N, et al. Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg. 1997;87(2):315-23.

  24. Krempien R, Muenter MW, Huber PE, Nill S, Friess H, Timke C, et al. Randomized phase II-study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer PARC: study protocol [ISRCTN56652283]. BMC Cancer. 2005;5:131.

  25. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Janne PA, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol. 2006;24:5253-8.

  26. Schrag D, Chung KY, Flombaum Current status of cetuximab for the treatment of patients with solid tumors.C, Saltz L. Cetuximabtherapy and symptomatichypomagnesemia. J Natl Cancer Inst. 2005;97(16):1221-4.

  27. Frieze DA, McCune JS. Current status of cetuximab for the treatment of patients with solid tumors. Ann Pharmacother. 2006;40(2):241-50.

  28. Dean NR, Sweeny L, Harari PM, Bonner JA, Jones V. Clemons L, et al. Wound healing following combined radiation and cetuximab therapy in head and neck cancer patients. J Wound Care. 2011;20:166-70.

  29. Fracasso PM, Burris H 3rd, Arquette MA, Govindan R, Gao F, Wright LP, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res. 2007;13:986-93.

  30. Velenik V, Ocvirk J, Oblak I, Anderluh F. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer. Eur J Surg Oncol. 2010;36(3):244-50.

  31. Schmitz S, Hamoir M, Reychler H, Magremanne M, Weynand B, Lhommel R, et al. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck. Ann Oncol. 2013 May 23. [Epub ahead of print] PMID: 23704200.

  32. Parikh AA, Ellis LM.Targeted therapies and surgical issues in gastrointestinal cancers. Targeted Oncol. 2008;3:119-25.

  33. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22:1646-54.

  34. Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, et al. Enhancement of the antitumor activity of ionizing radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in nonsmall cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer. 2008;98:749-55.

  35. González JE, Barquinero JF, Lee M, García O, Casacó A. Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells. Cancer Biol Ther. 2012;13:71-6.

  36. You B, Brade A, Magalhaes JM, Siu LL, Oza A, Lovell S, et al. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs. 2010;29:996-1003.

  37. Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res. 2010;16:2474-82.

  38. Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 2010;9:343-9.

  39. Allan D. Nimotuzumab: Evidence of clinical benefit without rash. The Oncologist. 2005;10:760-1.

  40. Saurez G, Cabanas R, Zaldívar M, Garnier T, Iglesias B, Piedra P, et al. Clinical experience with nimotuzumab in Cuban pediatric patients with brain tumors, 2005 to 2007. MEDICC Rev. 2009;11:27-33.

  41. Perez R, Moreno E, Garrido G, Crombet T. EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. Cancers. 2011;3:2014-31.

  42. Thomas F, Rochaix P, Benlyazid A, Sarini J, Rives M, Lefebvre JL, et al. Pilot study of neoadjuvant treatment with erlotinib in non-metastatic head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13(23):7086-92.

  43. Mellor J, Cassumbhoy M, Jefford M. Clinical guidance on the perioperative use of targeted agents in solid tumor oncology. Asia Pac J Clin Oncol. 2011;7:106-13.

  44. Govindan R, Behnken D, Read W, McLeod H. Wound healing is not impaired by the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib. Annals Oncol. 2003;14:1330-1.

  45. Garcia JA, Dreicer R. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Oncology (Williston Park). 2011;25:242-9.

  46. Rodriguez G, Gonzalez G, Crombet T, Lage A. Therapeutic vaccination with an EGF-based vaccine in lung cancer: a step in the transition to a chronic disease. Expert Rev Respir Med. 2011;5:337-42.

  47. Casacó A, Díaz Y, Ledón N, Merino N, Vadés O, Garcia G, et al. Effect of an egfcancer vaccine on wound healing and inflammation models. J Surg Res. 2004;122:130-4.

  48. Gonzalez G, Crombet T, Lage A. Chronic vaccination with a therapeutic EGFbased cancer vaccine: a review of patients receiving long lasting treatment. Curr Cancer Drug Targets. 2011;11:103-10.

  49. Fernández A, Acosta S, Neninger E, Barroso MC, Wilkinson B, Troche M, et al. Effect of blockade of EGF System on wound healing in patients vaccinated with CIMAvax® EGF. World J Surg Oncol. 2013;15:11(1):275.

  50. Ramírez BS, Pestana ES, Hidalgo GG, García TH, Rodríguez RP, Ullrich A, et al. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006;119:2190-99.

  51. Barro AM, Rivero AI, Goñi AL, Navarro BO, Angarica MM, Ramírez BS, et al. Non-clinical immuno-toxicological evaluation of HER1 cancer vaccine in non-human primates: a 12-month study. Vaccine 2012;31:89-95.

  52. Bell SW, Walker KG, Rickard MJ, Sinclair G, Dent OF, Chapuis PH, et al. Anastomotic leakage after curative anterior resection results in a higher prevalence of local recurrence. Br J Surg. 2003;90:126-6.

  53. Junemann-Ramirez M, Awan MY, Khan ZM, Rahamim JS. Anastomotic leakage post esophagogastrectomy for esophageal carcinoma: retrospective analysis of predictive factors, management and influence on long term survival in a high volume centre. Eur J Cardiothorac Surg. 2005;27:3-7.

  54. McArdle CS, McMillan DC, Hole DJ. Impact of anastomotic leakage on long-term survival of patients undergoing curative resection for colorectal cancer. Br J Surg. 2005;92:1150-4.

  55. Law WL, Choi HK, Lee YM, Ho JW, Seto CL. Anastomotic leakage is associated with poor long term outcome in patients after curative colorectal resection for malignancy. J Gastrointest Surg. 2007;11:8-15.

  56. Lee WS, Yun SH, Roh YN, Yun HR, Lee WY, Cho YB, et al. Risk factors and clinical outcome for anastomotic leakage after total mesorectal excision for rectal cancer. World J Surg. 2008;32:1124-9.

  57. Yoo HM, Lee HH, Shim JH, Jeon HM, Park CH, Song KY. Negative impact of leakage on survival of patients undergoing curative resection for advanced gastric cancer. J Surg Oncol. 2011;104:734-40.

  58. Licitra L, Perrone F, Tamborini E, Bertola L, Ghirelli C, Negri T, et al. Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. Ann Oncol. 2011;22:1886-93.

  59. Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet. 2003;362:527-33.

  60. Brusevold IJ, Aasrum M, Bryne M, Christoffersen T. Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells in vitro: role of MEK/ERK, p38 and PI-3 kinase/Akt. Oral Pathol Med. 2012;41:547-58.

  61. Sano D, Gule MK, Rosenthal DI, Bell D, Yates J, El-Naggar A, et al. Early postoperative epidermal growth factor receptor inhibition: Safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. Head Neck. 2013;35(3):321-8.

  62. Pickhard AC, Margraf J, Knopf A, Stark T, Piontek G, Beck C, et al. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways. BMC Cancer. 2011;11:388.




2020     |     www.medigraphic.com